BCM
AIMT

Bayesian Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Bayesian Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,621
Closed -$168K – 887
2020
Q1 		$168K Buy
+11,621
New +$297K 0.04% 613

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Bayesian Capital Management's AIMT Position: Q2 2020 in Review

Bayesian Capital Management sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 11,621 shares — an estimated $168K sold.

Bayesian Capital Management first reported a position in AIMT in Q1 2020 and held it in 1 quarter. The position peaked at $168K in Q1 2020. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • Bayesian Capital Management reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Bayesian Capital Management sold 11,621 Aimmune Therapeutics shares in Q2 2020, an estimated $168K.
  • Bayesian Capital Management first reported a position in Aimmune Therapeutics in Q1 2020 and held it in 1 quarter.
  • Bayesian Capital Management's Aimmune Therapeutics position peaked at $168K in Q1 2020.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Bayesian Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.